ClinicalTrials.gov
ClinicalTrials.gov Menu

Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03109847
Recruitment Status : Recruiting
First Posted : April 12, 2017
Last Update Posted : March 15, 2018
Sponsor:
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )

Brief Summary:
This pilot clinical trial studies how will metformin hydrochloride works in mitigating the side effects of radioactive iodine treatment in patients with differentiated thyroid cancer. Metformin hydrochloride may reduce the metabolic activity of cancer cell and of surrounding supportive tissues.

Condition or disease Intervention/treatment Phase
Thyroid Drug: Metformin Hydrochloride Other: Radioactive Iodine Other: Placebo Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine if treatment with metformin hydrochloride (metformin) inhibits radioactive iodine (RAI)-induced myelosuppression and induces faster recovery of white blood cell count to baseline values, the blood counts will be compared in the pre- and post-treatment samples.

SECONDARY OBJECTIVES:

I. Assess safety and tolerability of metformin treatment in subjects undergoing RAI treatment for differentiated thyroid cancer.

II. To determine the effect of metformin treatment on symptoms of xerostomia, xerophthalmia and dysgeusia as assessed by the Xerostomia Questionnaire (XQ), the modified Vanderbilt Head and Neck Cancer Symposium Survey (version 2.0), University of Washington Quality of Life Questionnaire, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQLQ)-Head and Neck (H&N)35.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Supportive Care
Official Title: Pilot Study of Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Well-Differentiated Thyroid Cancers
Actual Study Start Date : January 5, 2017
Estimated Primary Completion Date : June 8, 2021
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm I (metformin hydrochloride)
Patients receive metformin hydrochloride PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment.
Drug: Metformin Hydrochloride
Given Orally
Other Names:
  • 1,1-Dimethylbiguanide Hydrochloride
  • 1115-70-4
  • 91485
  • Cidophage
  • Dimefor
  • Glucoformin
  • Metformin HCl

Other: Radioactive Iodine
Undergo radioactive iodine treatment

Placebo Comparator: Arm II (placebo)
Patients receive placebo PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment
Other: Radioactive Iodine
Undergo radioactive iodine treatment

Other: Placebo
Given orally




Primary Outcome Measures :
  1. Complete blood count [ Time Frame: Up to 36 months of study duration ]
    Longitudinal measures of CBC will be modeled using mixed effects linear regression. Will use a linear contrast to test the null hypothesis that change from pre-resection to post-resection is the same in the control and metformin groups.

  2. Serum and salivary exosome profile [ Time Frame: Up to 36 months of study duration ]
    Will be modeled using mixed effects linear regression

  3. Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 36 months of study duration ]

Secondary Outcome Measures :
  1. Xerostomia assessed by modified Vanderbilt Head and Neck Cancer Symposium Survey (version 2.0) [ Time Frame: Up to 36 months of study duration ]
  2. Xerophthalmia assessed by modified Vanderbilt Head and Neck Cancer Symposium Survey (version 2.0) [ Time Frame: Up to 36 months of study duration ]
  3. Dysgeusia assessed by modified Vanderbilt Head and Neck Cancer Symposium Survey (version 2.0) [ Time Frame: Up to 36 months of study duration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with a diagnosis of differentiated thyroid cancer who have undergone total or near-total thyroidectomy and are candidates for iodine I-131 (I-131) treatment at Thomas Jefferson University Hospital (TJUH) are eligible to participate
  • Subjects must be diagnosed with differentiated thyroid cancer
  • Patients must have previously undergone or plan to undergo thyroidectomy; for those patients who have previously undergone surgery, pre-operative labs, including complete blood cell count with differential must be available
  • Patients who have a negative urine pregnancy test prior to enrollment. This should be done as part of pre-admission testing prior to surgery (within 14 days of study enrollment).
  • All subjects must be able to comprehend and sign a written informed consent document

Exclusion Criteria:

  • Subjects who are pregnant or may become pregnant during metformin administration in accordance with radioactive iodine treatment guidelines
  • Subjects on metformin for any reason during the preceding 4 weeks
  • Diabetic subjects are eligible if they are not taking metformin, insulin or sulfonylureas
  • Subjects who have received iodinated contrast dye. Metformin treatment can be started the day after subjects complete iodinated contrast treatment. If a CT scan with contrast is scheduled after screening and consent, the metformin treatment should be stopped the day before iodinated contrast administration. Metformin can be resumed on the day after last iodinated contrast was administered to the subject.
  • Patients with history of hepatic dysfunction or hepatic disease and abnormal liver function tests (previously documented alanine aminotransferase greater than 40 IU/dL and/or plasma aspartate aminotransferase greater than 45 IU/d); patients who have a history of hepatic dysfunction or hepatic disease but whose most recent liver function tests have been documented as normal will be eligible to participate
  • Patients with plasma creatinine level greater than 1.3 mg/dL
  • Patients with plasma alkaline phosphatase greater than 190 IU/dL
  • Patients with plasma bicarbonate less than 22 mEq/L or history of lactic or any other metabolic acidosis
  • Patients with history of congestive heart failure
  • Patients with myocardial ischemia or peripheral muscle ischemia
  • Patients with sepsis or severe infection
  • Patients with history of lung disease currently requiring any pharmacologic or supplemental oxygen treatment
  • Patients with a current history (in the past 30 days) of heavy drinking which is defined in accordance with CDC definition as more than 8 drinks per week for women and more than 15 drinks per week for men. A standard drink contains .6 ounces of pure alcohol. Generally, this amount of pure alcohol is found in 12-ounces of beer, 8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces or a "shot" of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey). While on study, patients should limit their alcohol consumption to no more than 8 drinks per week for women and no more than 15 drinks per week for men. Patients who feel they cannot comply with this recommendation are not eligible.
  • Patients with a systemic disease that could affect their bone marrow or peripheral blood cells (e.g. systemic lupus erythematosus, human immunodeficiency virus infection, rheumatoid arthritis)
  • Patients who have received or will receive medication that could affect their hematologic state (tyrosine kinase inhibitors, cytotoxic chemotherapy)
  • Patients who have received previous treatment with ionizing radiation
  • Patients who are Non-English speaking *Note: This is due to the nature of the study and the process for full translations of the study documents.

Due


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03109847


Contacts
Contact: Joseph Curry, MD (215) 955-6760

Locations
United States, Pennsylvania
Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Joseph Curry, MD    215-955-6760      
Sponsors and Collaborators
Sidney Kimmel Cancer Center at Thomas Jefferson University
Investigators
Principal Investigator: Joseph Curry, MD Sidney Kimmel Cancer Center at Thomas Jefferson University

Additional Information:
Responsible Party: Sidney Kimmel Cancer Center at Thomas Jefferson University
ClinicalTrials.gov Identifier: NCT03109847     History of Changes
Other Study ID Numbers: 16D.564
First Posted: April 12, 2017    Key Record Dates
Last Update Posted: March 15, 2018
Last Verified: March 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Metformin
Iodine
Cadexomer iodine
Hypoglycemic Agents
Physiological Effects of Drugs
Anti-Infective Agents, Local
Anti-Infective Agents
Trace Elements
Micronutrients
Growth Substances